TSOI (Therapeutic Solutions International) Research & Development: $0.24 Mil (TTM As of Sep. 2024)


What is Therapeutic Solutions International Research & Development?

Therapeutic Solutions International TSOI -99.00% Research & Development is $0.24 Mil as of Sep. 2024.

Research & Development is the aggregate amount of research and development expenses during the year. Therapeutic Solutions International's Research & Development for the three months ended in Sep. 2024 was $0.02 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was $0.24 Mil.

Therapeutic Solutions International  (OTCPK:TSOI) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Therapeutic Solutions International Research & Development Related Terms

Therapeutic Solutions International Research & Development Historical Data

* Premium members only.

The historical data trend for Therapeutic Solutions International's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therapeutic Solutions International Research & Development Chart

Therapeutic Solutions International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.56 0.80 1.45 0.56

Therapeutic Solutions International Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.15 0.06 0.02 0.02

Therapeutic Solutions International Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.24 Mil mean?
Therapeutic Solutions International (TSOI) has a Research & Development of $0.24 Mil as of Sep. 2024. Research and development expense is the total cost for research and development activities. View historical data on Therapeutic Solutions International and its competitors.
Is Therapeutic Solutions International's Research & Development too high?
Therapeutic Solutions International's current Research & Development is $0.24 Mil.
How does Therapeutic Solutions International's Research & Development compare to BPTH and RGBP?
Therapeutic Solutions International's Research & Development of $0.24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Therapeutic Solutions International and its competitors. Therapeutic Solutions International's current Research & Development is $0.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Therapeutic Solutions International stock overvalued right now?
Therapeutic Solutions International (TSOI) has a current Research & Development of $0.24 Mil. The current Research & Development is $0.24 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Therapeutic Solutions International (TSOI), the current Research & Development is $0.24 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Therapeutic Solutions International Business Description

Address 701 Wild Rose Lane, Elk City, ID, USA, 83525
Therapeutic Solutions International Inc focuses on immune modulation for the treatment of several specific diseases. It is engaged in developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. The business divisions of the company are Nutraceutical Division which produces nutraceuticals. Its current product, QuadraMune, is a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone. Cellular Division obtained exclusive rights to a patented adult stem cell for the development of therapeutics in the area of chronic traumatic encephalopathy and traumatic brain injury and Lung Pathology.